Home / 2020 / August

Monthly Archives: August 2020

Novavax and Canada Reach Agreement in Principle to Acquire Novavax’ COVID-19 Vaccine

•  Canadian government to purchase up to 76 million doses of NVX-CoV2373

GAITHERSBURG, Md., Aug. 31, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it has reached an agreement in principle with the Government of Canada to supply up to 76 million doses of NVX-CoV2373, Novavax’ COVID-19 vaccine.

“We are pleased to work with the Canadian government on supply of our COVID-19 vaccine, an essential step to ensure broad access of our vaccine candidate,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “We are moving forward with clinical development of NVX-CoV2373 with a strong sense of urgency in our quest to deliver a vaccine to protect the world.”

“We are pleased to announce this agreement with Novavax, which will give Canadians access to a promising COVID-19 vaccine candidate. This is an important step in our government’s efforts to secure a vaccine to keep Canadians safe and healthy, as the global pandemic evolves,” said The Honourable Anita Anand, Minister of Public Services and Procurement, Government of Canada.

Novavax and Canada expect to finalize an advance purchase agreement under which Novavax will supply doses of NVX-CoV2373 to Canada beginning as early as the second quarter of 2021. This purchase arrangement will be subject to licensure of the Novavax vaccine by Health Canada.

NVX-CoV2373 is currently in multiple Phase 2 clinical trials. The Phase 2 portion of the Phase 1/2 clinical trial to evaluate the safety and immunogenicity of NVX-CoV2373 began in August in the United States and Australia, and expands on the age range of the Phase 1 portion by including older adults 60-84 years of age as approximately 50 percent of the trial population. Secondary objectives include preliminary evaluation of efficacy. In addition, a Phase 2b clinical trial to assess efficacy began in South Africa in August.

About NVX-CoV2373

NVX‑CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS‑CoV‑2, the virus that causes COVID-19 disease. NVX‑CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax’ patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. In preclinical trials, NVX‑CoV2373 demonstrated indication of antibodies that block binding of spike protein to receptors targeted by the virus, a critical aspect for effective vaccine protection. In its Phase 1 data of the Phase 1/2 clinical trial, NVX‑CoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera. Phase 2 clinical trials began in August. Novavax has secured $2 billion in funding for its global coronavirus vaccine program, including up to $388 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI).

About Matrix-M™

Novavax’ patented saponin-based Matrix-M™ adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax is undergoing clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Novavax Forward-Looking Statements

Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading “Risk Factors” in the Novavax Annual Report on Form 10-K for the year ended December 31, 2019, and Quarterly Report on Form 10-Q for the period ended June 30, 2020, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Contacts:

Novavax

Investors
Silvia Taylor and Erika Trahan
ir@novavax.com
240-268-2022

Media
Brandzone/Speak Life Science
Amy Speak
amy@speaklifescence.com
617-420-2461

AIR Worldwide Estimates Insured Losses for Hurricane Laura Will be Between USD 4 Billion and USD 8 Billion

Boston, Aug. 31, 2020 (GLOBE NEWSWIRE) — Catastrophe risk modeling firm AIR Worldwide estimates that industry insured losses to onshore property resulting from Hurricane Laura’s winds and storm surge will range from USD 4 billion to USD 8 billion. AIR Worldwide is a Verisk (Nasdaq:VRSK) business.

“Although comparisons between Laura and Hurricane Rita (2005) have been made, they differ in two important ways: Rita was a larger storm and hit a more populous area than Laura did,” said Dr. Cagdas Kafali, senior vice president of research, AIR Worldwide. “Rita made landfall west of where Laura did, impacting population centers of Texas; Laura made landfall well east of Houston and west of New Orleans, keeping losses lower.”

Fueled by high sea surface temperatures in the Gulf of Mexico, Hurricane Laura made landfall near Cameron, Louisiana, close to the Texas border, on August 27 as a strong Category 4 storm, bringing catastrophic winds, around 15 feet of storm surge, and widespread heavy rain across the Gulf region, with wind and rain continuing north into Arkansas. AIR expects the combination of Laura’s track through relatively lower populated areas and its Rmax on the smaller side to keep insured losses down somewhat, despite its major hurricane status at landfall.

Laura struck the Louisiana coast with sustained winds of nearly 150 mph (241 km/h), tying it with the 1856 Last Island hurricane in terms of the strongest recorded tropical cyclone to make landfall in Louisiana. Laura’s rapid intensification over abnormally warm Gulf waters was similar to Hurricane Harvey (2017) and Hurricane Michael (2018), the other two most recent Category 4 or stronger storms to hit the U.S.

Wind damage was greatest in Louisiana, particularly in areas closer to the eyewall near landfall. Preliminary maximum wind reports from the National Weather Service (NWS) reported 133 mph gusts at Lake Charles in Calcasieu Parish. Reports show damage from torn off roofs and façades to structures that were destroyed, along with upended vehicles, damage to power lines, roads, railways, and other infrastructure.

Laura’s winds diminished after landfall but remained at hurricane strength for nearly half the day, pummeling the region for hours as the storm’s center traversed north through Louisiana. Laura’s storm surge was not as severe as expected, as the storm tracked a bit east of the Calcasieu Ship Channel, a waterway that connects the town of Lake Charles with the Gulf of Mexico, and pushed less water forward. The highest storm surge recorded thus far was around 15 feet above NAVD88 (around 17 feet above MLG), measured at a USACE river gauge on the Mermentau River at Grand Chenier (70900) in Cameron Parish County, Louisiana.

The vast majority of impacts were in Louisiana, as Hurricane Laura slammed the coastal town of Cameron, in Cameron Parish, and the town of Lake Charles, Calcasieu Parish, 30 miles from the coast, causing widespread destruction to buildings of all types.

Kafali concluded, “Residential buildings in and around Lake Charles saw significant damage to roofs of all geometries and with various roof cover types. Residential building envelopes were breached due to debris impacts and the damage was further exacerbated in many cases due to the impacts of storm surge. Residential homes in Louisiana are founded primarily on crawlspace and slab foundations, both of which are vulnerable when it comes to flood damage.”

About AIR Worldwide
AIR Worldwide (AIR) provides risk modeling solutions that make individuals, businesses, and society more resilient to extreme events. In 1987, AIR Worldwide founded the catastrophe modeling industry and today models the risk from natural catastrophes, terrorism, pandemics, casualty catastrophes, and cyber incidents. Insurance, reinsurance, financial, corporate, and government clients rely on AIR’s advanced science, software, and consulting services for catastrophe risk management, insurance-linked securities, longevity modeling, site-specific engineering analyses, and agricultural risk management. AIR Worldwide, a Verisk (Nasdaq:VRSK) business, is headquartered in Boston, with additional offices in North America, Europe, and Asia. For more information, please visit www.air-worldwide.com. For more information about Verisk, a leading data analytics provider serving customers in insurance, energy and specialized markets, and financial services, please visit www.verisk.com.

For more information, contact:
Kevin Long
AIR Worldwide
+1-617-267-6645
klong@air-worldwide.com

 

Philips EV300 ventilator supply contract with U.S. Department of Health and Human Services to end after delivery of 12,300 bundled ventilator configurations

August 31, 2020

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it has received notice from the U.S. Department of Health and Human Services (HHS) of the partial termination of the April 2020 contract to deliver 43,000 bundled EV300 ventilator configurations to HHS through December 2020. Philips will complete the deliveries for this month, resulting in a total of 12,300 bundled ventilator configurations supplied to the Strategic National Stockpile by the end of August 2020, in line with the contract. As directed by HHS, Philips will not supply the remaining 30,700 Philips EV300 ventilators to the Strategic National Stockpile.

Philips’ hospital ventilator contract with HHS was one of several contracts that the department announced in April 2020 for the production and delivery of a total of more than 156,000 ventilators to the Strategic National Stockpile by the end of August 2020, and a total of more than 187,000 ventilators by the end of the year [1].

“To date, we have delivered on our commitments to HHS,” said Frans van Houten, CEO of Royal Philips. “I am proud that with great urgency and under intense pressure, we achieved a fourfold ventilator production expansion with substantial investments: we hired hundreds of new colleagues for our factories in the U.S. and called upon our supply chain partners to massively step up, all in response to the COVID-19 pandemic. While we are disappointed in light of these vast efforts, we will adjust our plans and work with HHS to effectuate the partial termination of this contract.”

Frans van Houten added: “The COVID-19 pandemic is far from over, and we will continue to focus on our triple duty of care: meeting critical customer needs, ensuring business continuity, and safeguarding the health and safety of our employees. In the U.S., Philips is committed to work with the government and several of its agencies to support healthcare providers with the diagnosis, treatment, monitoring and management of COVID-19 patients, as well as the provision of regular health care.”

As the epicenter of the pandemic started to shift to the West in February 2020, Philips reached out to various governments around the world to discuss how to collaboratively combat COVID-19. From March 2020 onwards, Philips achieved a massive fourfold increase in ventilator production in just five months, adding production lines in the U.S. as well as creating hundreds of new jobs. Employees in Philips’ factories in Western Pennsylvania and California have been working around the clock to produce these ventilators.

Frans van Houten ended: “While we continue to see uncertainty and volatility related to the impact of COVID-19 across the world, our order book remains solid. The reduction in our ventilator deliveries to HHS will obviously impact Philips’ financial performance, but we continue to expect to return to growth and improved profitability in the second half of the year, starting in the third quarter. For the full year 2020, we now expect to deliver modest comparable sales growth with an Adjusted EBITA margin of around the level of last year.”

Philips has a comprehensive portfolio of products, services and solutions to support the delivery of high-quality care to COVID-19 patients worldwide. Solutions include secure, connected and intelligent approaches to diagnosis, treatment and predictive monitoring in the hospital, plus screening, remote patient monitoring and care at home. Philips’ telehealth and AI-enabled data analytics can help support workflows, facilitate remote collaboration and optimize resources. Philips’ COVID-19-related solutions are designed for rapid deployment and scalability.

[1] HHS Announces Ventilator Contract with Philips under Defense Production Act; HHS Announces Ventilator Contract with GM under Defense Production Act; HHS Announces New Ventilator Contracts, Orders Now Totaling Over 130,000 Ventilators; HHS Announces Ventilator Contract with GE Under Defense Production Act.

For further information, please contact:

Steve Klink
Philips Global Press Office
Tel.: +31 6 10888824
E-mail: steve.klink@philips.com

Leandro Mazzoni
Philips Investor Relations
Tel.: +31 20 59 77222
E-mail: leandro.mazzoni@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Forward-looking statements
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

Junshi Biosciences Announces Financial Results for Six Months Ended June 30, 2020 and Provides Corporate Updates

— Supplemental NDAs for Toripalimab filed
— Expanding into infectious disease and collaborating with IMCAS and Lilly for COVID-19 neutralizing antibodies
— Dual Listing on the STAR Market

SHANGHAI, China, Aug. 30, 2020 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced its financial results for the six months ended June 30, 2020 and provided corporate updates.

First Half 2020 Financial Highlights

  • Total revenues reached RMB575 million in the first half year of 2020, representing an 86% increase compared with the first half year of 2019. Sales of Toripalimab was RMB426 million, out of which RMB254 million was generated in the second quarter, representing recovery from the initial outbreak of COVID-19 in early 2020. Gross margin increased slightly to approximately 90% due to capacity utilization and productivity improvement. Sub-licensing and service income was RMB149 million. Junshi entered into a research collaboration and license agreement with Lilly and granted Lilly a license to conduct research, development and commercialization of JS016, an innovative drug for the treatment and prevention of COVID-19 in May 2020.
  • The research and development (“R&D”) expenses were RMB709 million in the first half year of 2020, representing an increase of 92% compared to RMB369 million for the same period in 2019. The increase was primarily due to progress of key clinical trials, more R&D collaboration and license-in activities expanding our pipelines to small molecule drugs, antibody drug conjugates (ADCs) and JS016.
  • The property, plant and equipment (“PPE”) by the end of June 2020 increased 11% to RMB2,026 million compared with the end of year 2019. The significant growth of the PPE was primarily due to the construction of the Lingang Production Base, which will enhance our current production capacity by ten fold.
  • Total comprehensive expense for the Reporting Period was RMB593 million, representing an increase of 105% compared to first half of 2019, mainly due to profit generated from Toripalimab sales, service income and sub-licensing income but offset by the increase in R&D expenses and administrative and selling expenses.
  • As of 30 June 2020, our bank and cash balances decreased to RMB676 million from RMB1,214 million as of 31 December 2019. The decrease was mainly due to: 1) investment in ongoing R&D projects, new R&D collaboration and license-in projects; 2) investment in and acquisition of companies in the pharmaceutical sector; and 3) investment in the production bases especially the Lingang Production Base. Subsequently, in July 2020, the company completed a public offering of A shares on the STAR Market of the Shanghai Stock Exchange and received gross proceeds of approximately RMB483.6 million.

Business Highlights

During the Reporting Period, we achieved significant progress with respect to our product commercialization, clinical trials and pipeline expansion. The Company’s products concentrated on self-developed biological products with original innovation. At the same time, through co-development and technology transfer/license-in, we further expanded our product pipeline. As of the end of the Reporting Period, we had 21 drug candidates, including 19 innovative drugs and 2 biosimilars, covering five major therapeutic areas including malignant tumors, autoimmune diseases, chronic metabolic diseases, neurologic diseases and infectious diseases.

  • During the Reporting Period, 15 pivotal registered clinical trials for Toripalimab were being conducted, in which 2 pivotal registered clinical trials were applied for NDA to the National Medical Products Administration (“NMPA”) and included in the process of priority review, covering a broad spectrum of indications, including: melanoma, urothelial carcinoma, nasopharyngeal carcinoma, non-small cell lung carcinoma, esophageal carcinoma, small cell lung carcinoma, triple negative breast carcinoma, hepatocellular carcinoma, gastric carcinoma and renal cell carcinoma.
    –  In March 2020, Toripalimab in combination with Axitinib for treatment of mucosal melanoma was granted the orphan-drug designation by the US Food and Drug Administration (“FDA”).
    –  In April and May 2020, the supplemental NDAs in respect of Toripalimab as a treatment for recurrent/metastatic NPC after failure of second-line and above systemic treatment and for locally advanced or metastatic urothelial carcinoma who received previous treatment were accepted by the NMPA, marking a new stage in the layout of indications in the segmented areas of Toripalimab. The two supplemental NDAs had been included in the process of priority review by the NMPA in July 2020.
    –  In June 2020, the Company and Merck KGaA entered into clinical trial collaboration in respect of the use of Toripalimab in combination with Cetuximab (Erbitux®) for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
  • The Company’s drug candidate TAB004/JS004 (a recombinant humanized anti-BTLA monoclonal antibody for injection) was approved for clinical trials in China by the NMPA, and the first patient was dosed in a Phase I clinical study in April 2020. In addition, its Phase I clinical study in the United States has completed dose-escalation study and entered dose-expansion stage.
  • The first subject was dosed in a Phase I clinical study of JS005 (a recombinant humanized anti-IL-17A monoclonal antibody for injection) in China in May 2020. At present, the Phase I clinical study has completed random enrollment.
  • In March 2020, the Company and the Institute of Microbiology, Chinese Academy of Sciences (“IMCAS”) entered into a project cooperation agreement to jointly develop and produce novel coronavirus neutralizing antibody JS016 (a recombinant fully human anti-SARS-CoV-2 monoclonal antibody for injection), an innovative drug for the treatment and prevention of COVID-19.
    –  In May 2020, the Company and Lilly entered into an agreement to collaborate on research, develop and commercialize potential preventive and therapeutic antibody therapies for COVID-19, and Lilly was granted an exclusive license to conduct research, develop and commercialize JS016 outside Greater China.
    –  In May 2020, the international authoritative journal “Nature” published the results of JS016 pre-clinical research, which reported for the first time that the neutralizing antibody of SARS-CoV-2 can significantly inhibit novel coronavirus infection in the test on non-human primate rhesus monkeys, showing the dual effect of treatment and prevention.
    –  In June 2020, JS016 was approved to conduct Phase I clinical trial in China, and the enrollment of subjects in the Phase I clinical trial was completed in July 2020. The international multi-center clinical trial was a randomized, double-blind and placebo controlled Phase I clinical study, aiming at evaluating the tolerability and safety of single-dose intravenous infusion of JS016 in healthy subjects. We plan to recruit 40 healthy subjects (including both male and female) as the world’s first novel coronavirus neutralizing antibody clinical trial conducted in healthy subjects. We are conducting Phase Ib international multi-center clinical studies for patients with mild/normal novel coronavirus pneumonia. And we expect to commence Phase II/III clinical study for patients with severe and critical novel coronavirus pneumonia as soon as possible. At the same time, the Company will also conduct follow-up studies on groups who are at high risks of the novel coronavirus to evaluate the preventive effect of JS016 on novel coronavirus infection.

After the Reporting Period, we continued to make significant progress in business operations including the following:

  • The Company applied to The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) and obtained approval for the dis-application of Rules 18A.09 to18A.11 of the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange (the “Hong Kong Listing Rules”) (the “Relevant Rules”) to the Company. As a result of the dis-application of the Relevant Rules, the “B” marker ceased to be affixed to the Company’s stock name and stock short name from 15 July 2020.
  • The Company completed the issue of A shares. The A shares of the Company were listed and commenced trading on the STAR Market of the Shanghai Stock Exchange on 15 July 2020.
  • The Company entered into a research collaboration and license agreement with Revitope Oncology, Inc. to develop next generation of T-cell engaging cancer immunotherapies that utilize Revitope’s proprietary dual-antigen targeting technology platform together with the Company’s antibody technology platform. Revitope will be responsible for designing up to 5 unique T-cell immunotherapeutic drugs against targets selected by the Company. The Company will be granted a world-wide exclusive license on products that result from such agreement.
  • The Company’s recombinant humanized anti-Trop2 monoclonal antibody – Tub196 conjugate for injection (product code: JS108), obtained the Clinical Trial Approval issued by the NMPA.
  • The Company and IMPACT Therapeutics entered into a joint venture agreement for the formation of a joint venture company (the “JV Company”). The JV Company will mainly engage in the R&D and commercialization of small molecule anti-tumor drugs. IMPACT Therapeutics will contribute for its equity interests by way of injection of a PARP inhibitor Senaparib (IMP4297) as an asset within mainland China, Hong Kong and the Macau Special Administrative Regions. The Company and IMPACT Therapeutics will each own 50% equity interests in the JV Company. Both parties will cooperate in conducting clinical trials, manufacturing, and commercialization preparations for various indications of the IMP4297 project within the above territory.

About Junshi Biosciences
Junshi Biosciences (HKEX: 1877; SSE: 688180) was co-established in December 2012 by alumni of famous universities of China and the United States. The founding team has extensive and solid experience in the cross-border transformation of scientific and technological achievements and substantial expertise in the pharmaceutical industry.

Our priority is researching and developing therapeutic antibodies. We are committed to researching, developing, and industrializing innovative monoclonal antibody drugs and other therapeutic protein drugs. The company has established a diversified R & D pipeline comprising 19 innovative candidate drugs and 2 biosimilars, with five therapeutic focus areas covering cancer, autoimmune diseases, metabolic diseases, neurologic diseases, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for PD-1 monoclonal antibody and clinical trial approval for anti PCSK9 monoclonal antibody from NMPA. The world’s first in human anti-BTLA antibody for solid tumors was officially approved for drug clinical trials by the FDA and NMPA. From this year onwards, Junshi Biosciences pooled its efforts with Chinese science institutions to co-develop JS016, China’s first neutralizing human monoclonal antibodies against SARS-Cov-2, that has entered clinical trial, part of our continuous innovation for disease control and prevention in China and beyond. We have about 2,000 employees in San Francisco and across Maryland in the United States, as well as Shanghai, Suzhou, Beijing, and Guangzhou, China. For more information, please visit: http://junshipharma.com.

Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-2250 0300

Solebury Trout
Bob Ai
bai@soleburytrout.com
+ 1 646.378.2926

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

Philips expands its dedicated cardiovascular ultrasound offering by launching Affiniti CVx for increased productivity

August 28, 2020

  • Philips introduces Affiniti CVx and Release 7.0 of EPIQ CVx with breakthrough interventional and productivity features to support cardiology departments managing everyday challenges
  • Philips debuts impactful solutions in cardiology at ESC 2020 (Aug 29 – Sept 1)

Amsterdam, The Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced today the latest addition to its portfolio of dedicated cardiovascular ultrasound solutions – Affiniti CVx – [1] for increased productivity. The system aims to support cardiology departments in delivering better care to more patients with increased efficiency and throughput.

With increasing patient volumes due to higher cardiac disease burden, clinicians are being asked to do more in less time and with fewer resources. The new Affiniti CVx enables a tailored workflow for cardiologists by integrating with a common platform that was first introduced with EPIQ CVx, the Philips premium cardiology ultrasound system. Affiniti CVx includes a familiar configurable UI, many popular automated tools and the sharing of transducers, now including TEE transducers, across the Affiniti CVx and EPIQ CVx systems.
Affiniti CVx will also feature AutoStrain technology, which has been shown to reduce strain analysis time by 70%. Together, these features will enable cardiology departments to standardize their ultrasound fleet for easier management, simplify cross-platform clinician training and reduce the total cost of ownership.

At ESC 2020, Philips debuts its new Affiniti CVx and release 7.0 for EPIQ CVx cardiovascular ultrasound solutions, which include improvements to enhance confidence in diagnosis and procedures, as well as improve the user experience.

“The COVID-19 pandemic has created an urgent need for nimble, user-friendly cardiac ultrasound solutions that can keep patients and healthcare providers safe while also generating the data needed to make confident decisions. With Release 7.0 of EPIQ CVx and Affiniti CVx, we’ve sharpened our focus on improving the cardiology experience by increasing the integration of our platforms to meet this demand,” said Dr. Alexandra Gonçalves, MD, MMSc, PhD, Cardiologist and Medical Officer for Cardiology and Personal Health at Philips. “Taken together, these releases help cardiology teams work faster and with greater precision and efficiency so that they can deliver the best possible heart care.”

Visit www.philips.com/affiniti-cvx for more information on Affiniti CVx, including a complete list of specifications.

Increasing confidence with the EPIQ CVx

Clinicians are needing to diagnose, plan treatments, monitor or follow up with patients more frequently. Philips EPIQ CVx provides a suite of features that can significantly reduce the time spent per patient, whether in the echo lab, at the patient bedside, or during procedures.

Release 7.0 for EPIQ CVx and EPIQ CVxi continues Philips leadership in interventional echocardiography and will provide new ways to better appreciate morphology, to size devices, and reduce the overall procedure time.

Industry-first dedicated tools such as 3D Auto LAA enable faster measurements of the left atrial appendage (LAA) from 3D increasing procedure efficiency. Cardiac TrueVue Color and Cardiac TrueVue Glass expand on the current Cardiac TrueVue photo realistic rendering by enhancing the visualization of flow, jet origin and morphology increasing clinician confidence.

Updates to the AutoStrain technology are among many additional new features to improve diagnostic confidence. AutoStrain updates will enhance confidence and efficiency in strain measurements while creating a 70% time saving in the acquisition and processing of images. These capabilities build on automated tools for strain and right heart measurements released in 2019, which have proven especially valuable in monitoring heart health in COVID-19 patients.

Philips at ESC
The ESC Congress 2020 will be held virtually from August 29 to September 2. Visit Philips Live! at ESC 2020 to learn more about events that Philips is hosting at ESC, schedule a live meeting or demonstration with a Philips team member, watch videos of cases, and register for the Philips ESC symposium on pushing the boundaries of cardiac visualization with an innovative echo toolkit. For more information about the symposium and other events, as well as general information about Philips’ presence at the ESC, visit www.philips.com/esc.

[1] Affiniti CVx has not yet received a CE mark and will not be marketed, put into service or otherwise made available in the EU until CE mark is received.

For further information, please contact:

Hans Driessen
Philips Global Press Office
Tel. : +31 6 10610417
Email : hans.driessen@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

Netflix unveils user interface in Bahasa Melayu

 

KUALA LUMPUR Netflix has launched its user interface (UI) in Bahasa Melayu that enables members in Malaysia to navigate the UI, read title names and synopses, and also watch shows and movies with Bahasa Melayu subtitles and dubs.

 

“Netflix believes in giving members control over their entire entertainment experience and surely will improve their viewing experience and better suit Malaysians who prefer consuming Netflix in their national language,” said a Netflix spokesperson in a  Zoom meeting on “Netflix Unveils New Feature For Malaysia”.

 

“The Bahasa Melayu UI option will give families more flexibility as members will be able to switch their profile to Bahasa Melayu from the language option that has up to 30 languages in the ‘Manage Profile’ section on their devices,” he added.

 

 

 

The complete Netflix experience in Bahasa Melayu, from sign-up to search rows, collections and payment, is available across all platforms including on phones, tablets, desktops, TV, even PlayStations.

 

The spokesman said that Netflix members can set up to five profiles in each account, and each profile can have its own language setting and even Netflix members outside of Malaysia will also have the option to switch their user interface to Bahasa Melayu.

 

Netflix also aims to bring Malaysian stories to a global audience and hence, on Sept 16, users will be able to watch the new show conducted by Dr Jason Leong: Hashtag Blessed, he added.

 

Source: BERNAMA News Agency

Bernama’s Rukun Negara Roadshow helps people appreciate national philosophy

ARAU Programmes and activities held during the 50th Rukun Negara anniversary celebration roadshow organised by the Malaysian National News Agency (BERNAMA) can help capture the people’s interest, especially the younger generations’, to learn about the principles of Rukun Negara.

 

Head librarian of the Tuanku Syed Faizuddin Putra Library at Universiti Malaysia Perlis (UniMAP) Mazmin Mat Akhir said the programmes also helped the university to remind the people of the philosophy behind the five principles of Rukun Negara.

 

“I am sure many have forgotten such as when the Rukun Negara was introduced. Hence, the roadshow by BERNAMA will help remind the people on the importance of the Rukun Negara which has been the recipe the country’s harmony and unity being preserved until today.

 

 

 

“Programmes organised by BERNAMA such as ‘Insta Challenge’, Rukun Negara Hour and e-Treasure Hunt are a good way to instil the patriotic spirit especially among the younger generations,” she told BERNAMA at the roadshow in UniMAP here, today.

 

BERNAMA organised the roadshow with the aim of enlivening the 50th Rukun Negara anniversary celebration.

 

At the programme, Mazmin also received promotional materials from the BERNAMA Perlis Bureau chief Ahmad Muliady Ab. Majid.

 

 

Meanwhile, roadshow co-ordinator Hasnita Ibrahim said Perlis was the seventh stop after Penang and it would make its next stops in Selangor, Pahang, Melaka and Johor ending on September 15.

 

 

Source: BERNAMA News Agency